ArticleCureus2026
Inpatient Initiation of Cobenfy (Xanomeline-Trospium Chloride) During Acute Psychotic Decompensation in a Patient With Schizoaffective Disorder: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xanomeline-trospium chloride (Cobenfy) is a novel muscarinic M1/M4 receptor agonist and a peripherally restricted antimuscarinic combination that represents a non-dopaminergic treatment approach for schizophrenia and related psychotic disorders. Although randomized clinical trials have demonstrated efficacy, published experience with inpatient initiation remains limited, particularly in patients undergoing transition from complex psychotropic polypharmacy. We describe the case of a 25-year-old nonbinary individual with schizoaffective disorder, depressive type, who was admitted for acute worsening of command auditory hallucinations and intermittent suicidal ideation in the setting of persistent psychotic symptoms despite multiple prior medication trials, including clozapine. During hospitalization, a structured medication wash was performed with sequential tapering and discontinuation of multiple psychotropic agents to reduce medication burden and clarify baseline symptomatology. Xanomeline-trospium was subsequently initiated and titrated to a therapeutic dose. Following initiation, the patient demonstrated improvement in the intensity and frequency of psychotic symptoms, resolution of active suicidal ideation by discharge, and good behavioral stability throughout hospitalization. The medication was well tolerated, with no extrapyramidal symptoms or other clinically significant adverse effects. This report highlights the feasibility and short-term tolerability of inpatient xanomeline-trospium initiation during a transition from complex psychotropic polypharmacy in a patient with acute psychotic decompensation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.